Summary & Overview
HCPCS S8085: F-18 FDG Imaging with Dual-Head Coincidence Detection
HCPCS Level II code S8085 designates Fluorine-18 fluorodeoxyglucose (F-18 FDG) imaging performed with a dual-head coincidence detection system — a non-dedicated PET imaging approach. This code captures FDG functional imaging when performed on coincidence detection systems that do not meet full dedicated PET scanner specifications. Nationally, S8085 is relevant for billing and utilization tracking of hybrid or alternative PET technologies used for oncologic and metabolic imaging when dedicated PET resources are unavailable or when facilities use coincidence-capable gamma cameras.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical and technical context for this service, typical sites of service, common billing modifiers associated with imaging lines, and what to expect in payer coverage considerations. The publication summarizes benchmark elements and policy-relevant points that affect reimbursement classification and claims adjudication for non-dedicated PET FDG imaging.
The report provides practical reference material for coding, billing, and compliance teams, including where S8085 fits among PET and nuclear medicine imaging codes, common billing scenarios, and the implications of using dual-head coincidence detection systems versus dedicated PET scanners. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S8085 describes Fluorine-18 fluorodeoxyglucose (F-18 FDG) imaging performed using a dual-head coincidence detection system (non-dedicated PET scan). The service is an FDG nuclear medicine imaging study that leverages a dual-head coincidence detector rather than a dedicated PET scanner.
Service type: Nuclear medicine positron emission imaging (non-dedicated PET/coincidence detection)
Typical site of service: Hospital outpatient department or freestanding imaging center where dual-head coincidence detection systems are available for FDG imaging
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of non-small cell lung cancer is referred for a whole-body metabolic imaging study to evaluate for recurrent or metastatic disease. The referring oncologist orders fluorine-18 fluorodeoxyglucose (F-18 FDG) imaging performed on a dual-head coincidence detection system (a non-dedicated PET scanner) to assess areas of increased glucose metabolism and guide management. The typical clinical workflow includes pre-procedure scheduling and screening for contraindications (e.g., recent high glucose level, recent isotopic imaging), patient fasting for at least 4–6 hours, measurement and documentation of blood glucose, intravenous administration of F-18 FDG, an uptake period (approximately 60 minutes) during which the patient rests quietly, and then imaging on the dual-head coincidence detection system. The imaging session is supervised by a nuclear medicine physician or qualified interpreting physician; technologists perform radiopharmaceutical preparation, injection, patient positioning, and acquisition. Image reconstruction and attenuation correction are applied as available for the non-dedicated system. The interpreting physician issues a structured report describing areas of abnormal FDG uptake, standardized uptake values when possible, and comparison with prior imaging. Typical site of service is an outpatient imaging center or hospital radiology/nuclear medicine department equipped with a dual-head coincidence detection gamma camera adapted for tomographic coincidence imaging rather than a dedicated PET/CT suite.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|